FrancophonIA/ELRC3.0 huggingface dataset:
English: What benefits of Rapamune have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Rapamune kasulikkus?
English: Rapamune is a medicine used to prevent the body from rejecting a newly transplanted kidney.
Estonian: Rapamune on ravim, mida kasutatakse äsja siiratud neeru äratõukereaktsiooni ennetamiseks.
English: In the body, sirolimus attaches to a protein inside cells to make a ‘complex'.
Estonian: Siroliimus seondub organismi rakkudes leiduva valguga, moodustades kompleksi.
English: Rapamune was more effective than placebo in improving lung function in a study involving 81 patients with S-LAM.
Estonian: Uuringus, milles osales 81 S-LAMiga patsienti, oli Rapamune kopsufunktsiooni parandamisel efektiivsem kui platseebo.
English: Rapamune was more effective than placebo (a dummy treatment) or azathioprine (another immunosuppressive medicine) in two main studies involving a total of 1,295 patients who were having a kidney transplant.
Estonian: Kahes põhiuuringus, milles osales kokku 1295 patsienti, kellele siirati neer, oli Rapamune efektiivsem kui platseebo (näiv ravim) või asatiopriin (samuti immuunsupressant).
English: The medicine can only be obtained with a prescription.
Estonian: Rapamune on retseptiravim.
English: Tibolona Aristo
Estonian: Tibolona Aristo 2,5 mg
English: Tibolon Aristo
Estonian: Tibolon Aristo 2,5 mg
English: The European Commission granted a marketing authorisation valid throughout the European Union for Tesavel on 10 January 2008.
Estonian: Euroopa Komisjon andis Tesaveli müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 10. Jaanuaril 2008.
English: The full EPAR for Tesavel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Tesaveli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This authorisation was based on the authorisation granted to Januvia in 2007 (‘informed consent').
Estonian: Müügiluba põhineb 2007. aastal antud Januvia müügiloal (teabel põhineva nõusoleku alusel).
English: Tesavel is taken at a dose of 100 mg once a day.
Estonian: Tesaveli võetakse annuses 100 mg üks kord ööpäevas.
English: • two studies compared Tesavel with other antidiabetes medicines.
Estonian: • Kahes uuringus võrreldi Tesaveli teiste diabeediravimitega.
English: For more information about treatment with Tesavel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Tesaveliga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: In patients with moderately or severely reduced kidney function the dose of Tesavel should be reduced.
Estonian: Keskmise või raske neerupuudulikkusega patsientidel tuleb Tesaveli annust vähendada.
English: This is a summary of the European public assessment report (EPAR) for Tesavel.
Estonian: See on ravimi Tesavel Euroopa avaliku hindamisaruande kokkuvõte.
English: Other information about Tesavel
Estonian: Muu teave Tesaveli kohta
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tesavel.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The CHMP decided that Tesavel's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee järeldas, et Tesaveli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Tesavel must not be used in people who are hypersensitive (allergic) to sitagliptin or any of the other ingredients.
Estonian: Tesaveli ei tohi kasutada patsiendid, kes on sitagliptiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Serious side effects reported with Tesavel include pancreatitis (inflammation of the pancreas) and hypersensitivity (allergic reactions).
Estonian: Ristabeni kohta teatatud rasked kõrvalnähud on muu hulgas pankreatiit (kõhunäärmepõletik) ja ülitundlikkus (allergilised reaktsioonid).
English: Why has Tesavel been approved?
Estonian: Miks Tesavel heaks kiideti?
English: What is Tesavel?
Estonian: Mis on Tesavel?
English: If Tesavel is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered to reduce the risk of hypoglycaemia (low blood sugar levels).
Estonian: Kui Tesaveli võetakse koos sulfonüüluurearavimi või insuliiniga, võib olla vaja vähendada sulfonüüluurearavimi või insuliini annust, et vähendada hüpoglükeemia (vere glükoosivaegus) riski.
English: Tesavel was studied in nine studies involving almost 6,000 patients with type 2 diabetes whose blood glucose levels were not adequately controlled:
Estonian: Tesaveli uuriti üheksas põhiuuringus, milles osales ligikaudu 6000 patsienti, kellel oli II tüüpi diabeet ja kelle organism ei reguleerinud vere glükoosisisaldust rahuldavalt.
English: When taken on their own, Tesavel and metformin produced similar reductions in HbA1c levels, but the effectiveness of Tesavel seemed to be slightly lower than that of metformin.
Estonian: Tesavel ja metformiin kasutatuna ainsa ravimina vähendasid sarnasel määral HbA1c-sisaldust, kuid Tesaveli efektiivsus näis olevat veidi väiksem kui metformiini efektiivsus.
English: In the studies comparing Tesavel with other medicines, the effectiveness of adding Tesavel to metformin was similar to that of adding glipizide.
Estonian: Uuringutes, kus Tesaveli võrreldi muude ravimitega, sarnanes metformiinile lisatud Tesaveli efektiivsus glipsiidile lisatud Tesaveli efektiivsusega.
English: • three additional studies compared Tesavel with placebo when they were added to other antidiabetes medicines: glimepiride (another sulphonylurea), with or without metformin, in 441 patients; the combination of metformin and rosiglitazone (a PPAR-gamma agonist) in 278 patients; and a stable dose of insulin, with or without metformin, in 641 patients.
Estonian: • Kolmes täiendavas uuringus võrreldi Tesaveli ja platseebot järgmistele diabeediravimitele lisamisel: glimepiriid (teatud sulfonüüluurearavim), koos metformiiniga või ilma, 441 patsiendil; metformiini ja rosiglitasooni (PPARγ agonist) kombinatsioon 278 patsiendil; insuliini püsiv annus koos metformiiniga või ilma 641 patsiendil.
English: What is the risk associated with Tesavel?
Estonian: Mis riskid Tesaveliga kaasnevad?
English: Tesavel is a medicine that contains the active substance sitagliptin.
Estonian: Tesavel on ravim, mille toimeaine on sitagliptiin.
English: Hypoglycaemia has been reported in combination with a sulphonylurea in 4.7-13.8% of patients and with insulin in 9.6% of patients.
Estonian: Nende patsientide osakaal, kellel on teatatud hüpoglükeemia esinemisest, on Tesaveli koos sulfonüüluurearavimiga kasutanute seas 4,7-13,8% ja Tesaveli koos insuliiniga kasutanute seas 9,6%.
English: For the full list of all side effects reported with Tesavel, see the package leaflet.
Estonian: Tesaveli kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What benefit has Tesavel shown during the studies?
Estonian: Milles seisneb uuringute põhjal Tesaveli kasulikkus?
English: How does Tesavel work?
Estonian: Kuidas Tesavel toimib?
English: The active substance in Tesavel, sitagliptin, is a dipeptidyl-peptidase-4 (DPP-4) inhibitor.
Estonian: Tesaveli toimeaine sitagliptiin on ensüümi dipeptidüülpeptidaas-4 (DPP-4) inhibiitor, mis blokeerib inkretiinhormoonide lagunemise organismis.
English: Tesavel was more effective than placebo when it was taken alone or in combination with other antidiabetes medicines.
Estonian: Tesavel oli kasutamisel ainsa ravimina või koos teiste diabeediravimitega efektiivsem kui platseebo.
English: Tesavel is used in patients with type 2 diabetes to improve the control of blood glucose (sugar) levels.
Estonian: Tesaveli kasutatakse II tüüpi diabeediga (suhkurtõvega) patsientide raviks, et parandada vere glükoosisisalduse reguleeritavust organismis.
English: In patients taking Tesavel on its own, HbA1c levels fell from around 8.0% at the start of the studies by 0.48% after 18 weeks and 0.61% after 24 weeks.
Estonian: Tesaveli ainsa ravimina kasutanud patsientidel vähenes HbA1c-sisaldus väärtuselt ligikaudu 8,0% uuringu alguses 18 nädala järel 0,48% võrra ja 24 nädala järel 0,61% võrra.
English: In the additional studies, adding Tesavel to glimepiride (with and without metformin) led to a reduction in HbA1c levels of 0.45% after 24 weeks, compared with an increase of 0.28% in the patients adding placebo.
Estonian: Täiendavates uuringutes, kus Tesaveli lisati glimepiriidile (koos metformiiniga või ilma) vähenes 24 nädala järel glükohemoglobiini sisaldus 0,45% võrra, platseebo lisamisel suurenes selle sisaldus 0,28% võrra.
English: What is Tesavel used for?
Estonian: Milleks Tesaveli kasutatakse?
English: How has Tesavel been studied?
Estonian: Kuidas Tesaveli uuriti?
English: How is Tesavel used?
Estonian: Kuidas Tesaveli kasutatakse?
English: The medicine can only be obtained with a prescription.
Estonian: Tesavel on retseptiravim.
English: Tesavel or placebo were used on their own in two studies involving 1,262 patients, as an add-on to metformin in one study involving 701 patients, and as an add-on to pioglitazone (a PPAR-gamma agonist) in one study involving 353 patients;
Estonian: • Neljas uuringus võrreldi Tesaveli platseeboga (näiv ravim): neist kahes (1262 patsienti) vaadeldi Tesaveli või platseebo kasutamist ainsa ravimina, kolmandas (701 patsienti) lisati kumbagi metformiinile ja neljandas (353 patsienti) lisati kumbagi PPARγ agonistile pioglitasoonile.
English: • in combination with both metformin and a sulphonylurea or a PPAR-gamma agonist, in patients who are not satisfactorily controlled on the two medicines;
Estonian: • koos metformiini ja sulfonüüluurearavimi või PPARγ agonisti kombinatsiooniga patsientidel, kelle vere glükoosisisaldust kummagi ravimiga rahuldavalt reguleerida ei saa;
English: Adding Tesavel to metformin reduced HbA1c levels by 0.67% after 24 weeks, compared with a fall of 0.02% in the patients adding placebo.
Estonian: Tesaveli lisamisel metformiinile vähenes 24 nädala järel HbA1c-sisaldus veres 0,67% võrra, platseebo korral vähenes 0,02% võrra.
English: One study compared Tesavel with glipizide (a sulphonylurea), when they were used as an add-on to metformin in 1,172 patients.
Estonian: Ühes uuringus (1172 patsienti) võrreldi Tesaveli glipisiidiga (teatud sulfonüüluurearavim) kummagi lisamisel metformiinile.
English: HbA1c levels were reduced by 1.03% after 18 weeks in patients adding Tesavel to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo.
Estonian: Tesaveli lisamisel metformiinile ja rosiglitasoonile vähenes 18 nädala järel HbA1c-sisaldus veres 1,03% võrra ja platseebo lisamisel vähenes sisaldus 0,31% võrra.
English: The other study compared Tesavel with metformin, used on their own, in 1,058 patients;
Estonian: Teises uuringus (1058 patsienti) võrreldi Tesaveli ja metformiini kasutamist ainsa ravimina.
English: When added to pioglitazone, Tesavel reduced HbA1c levels by 0.85% after 24 weeks, compared with a fall of 0.15% in the patients adding placebo.
Estonian: Tesaveli lisamisel pioglitasoonile vähenes 24 nädala järel HbA1csisaldus veres 0,85% võrra, platseebo korral vähenes 0,15% võrra.
English: Finally, they were reduced by 0.59% in patients adding Tesavel to insulin (with or without metformin), compared with a fall of 0.03% in those adding placebo.
Estonian: Tesaveli lisamisel insuliinile (koos metformiiniga või ilma) vähenes HbA1c-sisaldus veres 0,59% võrra, platseebo lisamisel vähenes sisaldus 0,03% võrra.
English: 1 See outcome of safety review carried out in 2018 here.
Estonian: 1 Vt 2018. aastal koostatud ohutusteabe ülevaadet siin.
English: Xofigo received a marketing authorisation valid throughout the EU on 13 November 2013.
Estonian: Xofigo on saanud müügiloa, mis kehtib kogu ELis, 13. novembril 2013.
English: The medicine is slowly injected into a vein usually for up to one minute.
Estonian: Ravim süstitakse aeglaselt veeni, tavaliselt kuni ühe minuti jooksul.
English: What measures are being taken to ensure the safe and effective use of Xofigo?
Estonian: Mis meetmed võetakse, et tagada Xofigo ohutu ja efektiivne kasutamine?
English: Further information on Xofigo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Xofigo kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Medicines Agency decided that Xofigo's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Xofigo kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Injections are repeated every 4 weeks for a total of 6 injections.
Estonian: Süste korratakse iga 4 nädala järel, manustades kokku 6 süsti.
English: Patients were given up to 6 injections at 1-month intervals and were followed up for 3 years from the first injection.
Estonian: Patsiendid said ühekuiste intervallidega kuni 6 süsti ja neid jälgiti kuni 3 aasta jooksul pärast esimest süsti.
English: This may limit the damage to nearby healthy tissues.
Estonian: See võib piirata ümbritsevate tervete kudede kahjustust.
English: Other information about Xofigo
Estonian: Muu teave Xofigo kohta
English: It should be used only for patients who have had at least two previous treatments for prostate cancer or who cannot receive other treatments.
Estonian: Seda tohivad kasutada ainult patsiendid, kes on varem saanud eesnäärmevähi ravi vähemalt kahel korral või kellele muu ravi ei sobi.
English: Xofigo can increase the risk of having fractures.
Estonian: Xofigo võib suurendada luumurdude riski.
English: As for all medicines, data on the use of Xofigo are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Xofigo kasutamise kohta pidevat järelevalvet.
English: The bones in the body take up radium in the same way as calcium.
Estonian: Luud talletavad organismis raadiumi samal viisil nagu kaltsiumi.
English: The radioactive radium builds up in bone tissues where the cancer has spread, and the alpha particles destroy surrounding cancer cells and help to control the associated symptoms.
Estonian: Radioaktiivne raadium koguneb luukoesse, kuhu vähk on levinud, ning alfaosakesed hävitavad ümbritsevad vähirakud ja aitavad ohjata seotud sümptomeid.
English: What is Xofigo and what is it used for?
Estonian: Mis on Xofigo ja milleks seda kasutatakse?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xofigo have also been included in the summary of product characteristics and the package leaflet.
Estonian: Xofigo ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Patients given Xofigo lived on average for 14.9 months, compared with 11.3 months for those given placebo.
Estonian: Xofigot kasutanud patsientide keskmine elumus oli 14,9 kuud ja platseebot kasutanud patsientidel 11,3 kuud.
English: Side effects reported with Xofigo are carefully evaluated and any necessary action taken to protect patients.
Estonian: Xofigo kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Xofigo is used when castration (to stop the production of male hormones) by surgery or with medicines does not work, and when the cancer has spread to the bones (bone metastases) and is causing symptoms such as pain, but has not spread to other internal organs.
Estonian: Xofigot kasutatakse juhul, kui kirurgiline või ravimitega tehtav kastreerimine (meessuguhormoonide tootmise peatamiseks) ei toimi ning kui vähk on levinud luudesse (luumetastaasid) ja põhjustab selliseid sümptomeid nagu valu, kuid ei ole levinud teistesse siseelunditesse.
English: For more information about using Xofigo, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Xofigo kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Xofigo is used on its own or in combination with a medicine known as an ‘LHRH analogue'.
Estonian: Xofigot kasutatakse ainuravimina või koos ravimiga, mida nimetatakse LHRH analoogiks.
English: Xofigo has been shown to prolong life and delaying signs and symptoms of progressive disease.
Estonian: Xofigo on tõendite kohaselt efektiivne elumuse pikendamisel ning progresseeruva haiguse nähtude ja sümptomite tekke edasilükkamisel.
English: The most common side effects with Xofigo (which may affect more than 1 in 10 people) are diarrhoea, nausea (feeling sick), vomiting, thrombocytopenia (low blood-platelet counts) and bone fractures.
Estonian: Xofigo kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on kõhulahtisus, iiveldus, oksendamine, trombotsütopeenia (trombotsüütide ehk vereliistakute vähesus) ja luumurrud.
English: The company that markets Xofigo will have to conduct studies to further characterise the safety profile of the medicine, in particular with regard to the risk of fractures and the risk of new metastases that do not affect the bone in patients treated with Xofigo.
Estonian: Xofigo turustaja peab korraldama uuringud ravimi ohutusprofiili täiendavaks kirjeldamiseks, eelkõige seoses luumurruriskiga ning mujal kui luudes tekkivate uute metastaaside riskiga Xofigoga ravitavatel patsientidel.
English: Xofigo was compared with placebo (a dummy treatment) as an addition to standard care in a main study involving 921 men with cancer of the prostate that had spread to the bones and for which suppression of male hormones using medicines or surgery did not work.
Estonian: Xofigot võrreldi platseeboga (näiv ravim) standardravi lisandina põhiuuringus, milles osales 921 eesnäärmevähiga meest, kelle vähk oli levinud luudesse ja kellel meessuguhormoonide pärssimine ravimitega või kirurgiliselt ei toiminud.
English: Xofigo must not be used with the medicine abiraterone acetate and the corticosteroids prednisone or prednisolone.
Estonian: Xofigot ei tohi kasutada koos abirateroonatsetaadi (teatav ravim) ega kortikosteroidide prednisooni või prednisolooniga.
English: Xofigo is a radiopharmaceutical (a medicine containing a radioactive substance) that is used to treat adults with cancer of the prostate (a gland of the male reproductive system).
Estonian: Xofigo on radiofarmatseutikum (radioaktiivset ainet sisaldav ravim), mida kasutatakse eesnäärmevähiga täiskasvanute raviks (eesnääre on meeste reproduktiivsüsteemi nääre).
English: What are the risks associated with Xofigo?
Estonian: Mis riskid Xofigoga kaasnevad?
English: Xofigo (radium-223 dichloride)
Estonian: Xofigo (raadium-223 dikloriid)
English: For the full list of side effects of Xofigo, see the package leaflet.
Estonian: Xofigo kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The most serious side effects were thrombocytopenia and neutropenia (low levels of neutrophils, a type of white blood cell that fights infection).
Estonian: Kõige raskemad kõrvalnähud olid trombotsütopeenia ja neutropeenia (neutrofiilide ehk teatud infektsioonivastaste valgeliblede vähesus).
English: How does Xofigo work?
Estonian: Kuidas Xofigo toimib?
English: Xofigo can only be obtained with a prescription and should only be handled and given by someone who is authorised to use radioactive medicines and after evaluation of the patient by a qualified doctor.
Estonian: Seda tohivad käsitseda ja manustada ainult radioaktiivsete ravimite kasutamiseks volitatud isikud pärast seda, kui patsiendi tervislikku seisundit on hinnanud kvalifitseeritud arst.
English: How is Xofigo used?
Estonian: Kuidas Xofigot kasutatakse?
English: Xofigo contains the active substance radium-223 dichloride.
Estonian: Xofigo sisaldab toimeainena raadium-223 dikloriidi.
English: The active substance in Xofigo, radium-223, emits short-range radiation known as alpha particles.
Estonian: Xofigo toimeaine raadium-223 kiirgab väikese leviulatusega kiirgust, mida nimetatakse alfaosakesteks.
English: The dose of Xofigo is calculated to provide a specific dose of radioactivity based on the patient's body weight.
Estonian: Xofigo annus arvutatakse patsiendi kehakaalu alusel, et saada kindel radioaktiivsuse annus.
English: What benefits of Xofigo have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Xofigo kasulikkus?
English: An overview of Xofigo and why it is authorised in the EU
Estonian: Ülevaade ravimist Xofigo ja ELis müügiloa väljastamise põhjendus
English: Regarding its safety, several measures have been put in place to minimise the risks of the medicine such as bone fractures1 The radiation emitted by Xofigo has a shorter range than the radiation of currently available radiopharmaceuticals.
Estonian: Ohutuse seisukohast on kehtestatud mitu meedet ravimiga seotud riskide, näiteks luumurruriski vähendamiseks1.
English: The signs and symptoms of progressive disease such as bone pain also took longer to develop in patients given Xofigo.
Estonian: Xofigot kasutanud patsientidel kulus ka kauem aega progresseeruva haiguse nähtude ja sümptomite (nt luuvalu) tekkeni.
English: These changes were each in the direction of improved lipid responses and were sustained over 2 years.
Estonian: Iga selline muutus toimus lipiidvastuse paranemise suunas ning püsis üle 2 aasta.
English: What you need to know before you take CRESTOR
Estonian: Mida on vaja teada enne Crestori kasutamist
English: Children younger than 6 years
Estonian: Alla 6-aastased lapsed
English: Treatment of hypercholesterolaemia
Estonian: Hüperkolesteroleemia ravi
English: The product information may be subsequently updated by the Member State competent authorities, in liaison with the Reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC.
Estonian: Vastavalt vajadusele ja koostöös referentsriigiga võivad liikmesriikide pädevad asutused ravimiinfot edasiselt uuendada kooskõlas direktiivi 2001/83/EC III jaotise 4. peatükis sätestatud protseduuridega.
English: • You have other factors that increase your risk of having a heart attack, stroke or related health problems.
Estonian: - teil on teised riskitegurid, mis tõstavad teie riski haigestuda südamelihaseinfarkti, ajurabandusse või sarnastesse terviseprobleemidesse.
English: This trial (n=176) was not suited for comparison of rare adverse drug events.
Estonian: Käesolevas uuringus (n=176) ei vaadeldud harvaesinevaid kõrvaltoimeid.
English: Your doctor may increase your dose to find the right amount of CRESTOR for you.
Estonian: Teie arst võib otsustada annust suurendada selleks, et leida teile sobiv Crestori annus.
English: Rosuvastatin exposure was predictable with respect to dose and time over a 2-year period.
Estonian: Rosuvastatiini plasmatasemed olid ennustatavad, arvestades annust ja aega 2-aastase perioodi jooksul.
English: • If the patient is under 6 years old: CRESTOR should not be given to children younger than 6 years.
Estonian: • Kui patsient on alla 6-aastane: Crestorit ei tohi anda alla 6-aastastele lastele.
English: Crestor is used in adults, adolescents and children 6 years or older to treat high cholesterol.
Estonian: Crestorit kasutatakse täiskasvanutel, noorukitel ja 6-aastastel või vanematel lastel kõrge kolesteroolitaseme raviks.
English: The starting dose for all patients was 5 mg rosuvastatin once daily.
Estonian: Algannus kõigile patsientidele oli 5 mg rosuvastatiini üks kord ööpäevas.
English: [The wording of the indication for treatment of hypercholesterolaemia should be replaced with the following:]
Estonian: [Hüperkolesteroleemia ravi näidustuste sõnastus asendatakse järgmisega:]